{"id":1042668,"date":"2011-11-27T16:56:18","date_gmt":"2011-11-27T16:56:18","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/another-indication-that-age-is-a-low-barrier-to-cell-therapies\/"},"modified":"2024-08-17T16:59:10","modified_gmt":"2024-08-17T20:59:10","slug":"another-indication-that-age-is-a-low-barrier-to-cell-therapies","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/longevity-medicine\/another-indication-that-age-is-a-low-barrier-to-cell-therapies.php","title":{"rendered":"Another Indication that Age is a Low Barrier to Cell Therapies"},"content":{"rendered":"<p>There have been a number of research results in the past year or two that suggest the barriers posed by age to the production of patient-specific cells suitable for <a href=\"http:\/\/en.wikipedia.org\/wiki\/Stem_cell_therapy\">stem cell therapies<\/a> are <a href=\"http:\/\/www.fightaging.org\/archives\/2009\/12\/are-cells-from-old-people-still-good-for-therapeutic-use.php\">lower than first thought<\/a>. Several research groups have obtained useful cells from old patients, showing that age-related damage to patient cells is no barrier to <a href=\"http:\/\/en.wikipedia.org\/wiki\/Induced_pluripotent_stem_cell\">reprogramming them<\/a> - indeed, the reprogramming <a href=\"http:\/\/www.fightaging.org\/archives\/2010\/12\/mitochondrial-rejuvenation-via-induced-pluripotency-techniques.php\">appears to repair many types of damage<\/a>. Here is another such result: \"Somatic cells reprogrammed into <a href=\"http:\/\/en.wikipedia.org\/wiki\/Induced_pluripotent_stem_cell\">induced pluripotent stem cells (iPSCs)<\/a> acquire features of human <a href=\"http:\/\/en.wikipedia.org\/wiki\/Embryonic_stem_cell\">embryonic stem cells<\/a> (hESCs) and thus represent a promising source for cellular therapy of debilitating diseases, such as age-related disorders. ... Aged somatic cells might possess high susceptibility to nuclear and mitochondrial genome instability. Hence, concerns over the [potential of reprogrammed cells to spawn cancer] due to the lack of genomic integrity may hinder the applicability of iPSC-based therapies for age-associated conditions. ... Four iPSC lines were generated from dermal fibroblasts derived from an 84-year-old woman, representing the oldest human donor so far reprogrammed to pluripotency. ... all aged-iPSCs were able to differentiate into <a href=\"http:\/\/en.wikipedia.org\/wiki\/Neuron\">neurons<\/a>, re-establish <a href=\"http:\/\/en.wikipedia.org\/wiki\/Telomerase\">telomerase<\/a> activity, and reconfigure <a href=\"http:\/\/en.wikipedia.org\/wiki\/Mitochondrion\">mitochondrial<\/a> ultra-structure and functionality to a hESC-like state. Importantly, aged-iPSCs exhibited high sensitivity to drug-induced <a href=\"http:\/\/en.wikipedia.org\/wiki\/Apoptosis\">apoptosis<\/a> and low levels of <a href=\"http:\/\/en.wikipedia.org\/wiki\/Oxidative_stress\">oxidative stress<\/a> and <a href=\"http:\/\/en.wikipedia.org\/wiki\/DNA_damage\">DNA damage<\/a>, in a similar fashion as iPSCs derived from young donors and hESCs. Thus, the occurrence of <a href=\"http:\/\/en.wikipedia.org\/wiki\/Chromosome\">chromosomal<\/a> abnormalities within aged reprogrammed cells might not be sufficient to over-ride the cellular surveillance machinery and induce malignant transformation through the alteration of mitochondrial-associated cell death. Taken together, we unveiled that cellular reprogramming is capable of reversing aging-related features in somatic cells from a very old subject, despite the presence of genomic alterations.\"<\/p>\n<p><span>Link: <a href=\"http:\/\/dx.doi.org\/10.1371\/journal.pone.0027352\">http:\/\/dx.doi.org\/10.1371\/journal.pone.0027352<\/a><\/span><\/p>\n<p>Source:<br \/><a href=\"http:\/\/www.longevitymeme.org\/newsletter\/latest_rss_feed.cfm\">http:\/\/www.longevitymeme.org\/newsletter\/latest_rss_feed.cfm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>There have been a number of research results in the past year or two that suggest the barriers posed by age to the production of patient-specific cells suitable for stem cell therapies are lower than first thought. Several research groups &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/longevity-medicine\/another-indication-that-age-is-a-low-barrier-to-cell-therapies.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246678],"tags":[],"class_list":["post-1042668","post","type-post","status-publish","format-standard","hentry","category-longevity-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1042668"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1042668"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1042668\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1042668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1042668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1042668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}